{"title":"FDA advisers greenlight Pfizer boosters for people 65+ and at-risk groups","link":"https://arstechnica.com/?p=1796430","date":1631916593000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2020/12/GettyImages-1229751608-800x534.jpg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2020/12/GettyImages-1229751608.jpg\">Enlarge</a> <span>/</span> Vials with COVID-19 Vaccine labels showing logos of pharmaceutical company Pfizer and German biotechnology company BioNTech. (credit: <a href=\"https://www.gettyimages.com/search/photographer?family=editorial&amp;photographer=Photonews\">Getty | Photonews</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>A committee of independent advisers for the Food and Drug Administration has voted unanimously (18-0) in favor of authorizing a booster dose of the Pfizer/BioNTech COVID-19 vaccine for people age 65 and older, as well as people at high risk based on an underlying medical condition and/or occupational exposure (e.g., health care workers). The booster doses are recommended to be given at least six months after completion of the primary two doses.</p>\n<p>If the FDA moves forward with the advisory committee's recommendation—which it likely will—boosters will be offered to those two groups based on an Emergency Use Authorization.</p>\n<p>Prior to voting in favor of authorization for the two groups, the committee rejected the idea of approving boosters for all people ages 16 and up with a resounding vote of 16-2 against.</p></div><p><a href=\"https://arstechnica.com/?p=1796430#p3\">Read 18 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1796430&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"08c560962cdef525befea3f84b4508c33dc77d9f04cf1db88bdb5d7a4ceb3e85","category":"Tech"}